Screener
AtriCure ATRC Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by AtriCure in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: AtriCure’s 10-Q, filed July 27, 2026.
- Filed
- Jul 27, 2026, 1:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001323885-26-000035
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Effect of exchange rate changes on cash and cash equivalents | (227) | 733 |
| Net increase (decrease) in cash and cash equivalents | 358 | (4,925) |
| Cash and cash equivalents—beginning of period | 167,428 | 122,721 |
| Cash and cash equivalents—end of period | $167,786 | $117,796 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $2,385 | $2,574 |
| Cash paid for taxes, net of refunds | 1,053 | 882 |
| Non-cash investing and financing activities: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is AtriCure's cash & equivalents?
- AtriCure (ATRC) reported cash & equivalents of $167.79M in Q2 2026.
- How has AtriCure's cash & equivalents changed year-over-year?
- AtriCure's cash & equivalents increased by 42.4% year-over-year, from $117.8M to $167.79M.
- What is the long-term trend for AtriCure's cash & equivalents?
- Over 5 years (2020 to 2025), AtriCure's cash & equivalents has grown at a 31.9% compound annual growth rate (CAGR), from $41.94M to $167.43M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about AtriCure's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude